Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug

by Zacks Equity Research

Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.

Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why

by Zacks Equity Research

Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Novo Nordisk (NVO) Rides on Ozempic & Wegovy Amid Rivalry

by Zacks Equity Research

Novo Nordisk (NVO) continues to witness increasing demand for its diabetes and obesity care products like Ozempic, Wegovy and Rybelsus amid rising competition from other pharma bigwigs.

Ethan Feller headshot

Prescribing Profits: 3 Stocks to Ride the Healthcare Relative Strength

by Ethan Feller

Over the last month, Healthcare has been the second strongest sector in the market

Nektar (NKTR) Stock Surges 75% in a Week: Here's Why

by Zacks Equity Research

Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.

MacroGenics' (MGNX) Shares Jump 19% in One Week: Here's Why

by Zacks Equity Research

MacroGenics (MGNX) shares increase after it reported a surge in Q2 earnings per share. A $50-million milestone payment from Sanofi was also triggered last month.

Sweta Killa headshot

Pharma ETFs in Focus Post Q2 Earnings

by Sweta Killa

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, BAYRY Post Q2 Results, NVO's Wegovy Cuts Heart Attack Risk

by Kinjel Shah

Eli Lilly (LLY), Bayer (BAYRY) and Novo Nordisk (NVO) announce second-quarter results.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Sweta Killa headshot

Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap

by Sweta Killa

Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.

Company News for Aug 9, 2023

by Zacks Equity Research

Companies in The News Are:LLY,UAA,ATKR,HZNP

Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss

by Zacks Equity Research

Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.

Zacks Investment Ideas feature highlights: DraftKings, Eli Lilly and Emerson Electric

by Zacks Equity Research

DraftKings, Eli Lilly and Emerson Electric have been highlighted in this Investment Ideas article.

Derek Lewis headshot

3 Stocks to Buy Following Beat-and-Raise Quarters

by Derek Lewis

All three of these stocks saw buying pressure following better-than-expected results. Should investors ride the earnings momentum?

Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth

by Zacks Equity Research

Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.

U.S. Trade Deficit Decreased in June

by Zacks Equity Research

U.S. Trade Deficit Decreased in June

Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Mark Vickery headshot

Pre-Markets Give Back Some Gains; UPS, LLY, QSR Report

by Mark Vickery

Off mid-July highs for the year, we've been a bit more bipolar -- and decidedly to the downside since the start of August.

Eli Lilly (LLY) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Lilly (LLY) delivered earnings and revenue surprises of 6.57% and 10.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Indices Fight Back; PLTR Meets, SWKS and PARA Beat

by Mark Vickery

The Dow climbed back +408 points on the day, +1.16%, while the Nasdaq gained +84 points, +0.61%.

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More

by Kinjel Shah

Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.

Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Eli Lilly's (LLY) second-quarter sales.

Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.